Further, we evaluated CSPG4 and FGF13 expression in MET and observed a non-significant or only partially significant difference in expression of CSPG4 or FGF13 among primary and metastatic melanoma (SI, Figures S13D, left panels; S13E and S14A), respectively. This evidence concerns the gene CSPG4 and metastatic melanoma.